New drug aims to lower dangerous blood fats in heart patients

NCT ID NCT06797401

Recruiting now Disease control Sponsor: Ribocure Pharmaceuticals AB Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025 · Last updated May 24, 2026 · Updated 28 times

Summary

This study tests an experimental drug called RBD5044 in 120 adults with mixed dyslipidemia, a condition where blood fats like triglycerides and cholesterol are too high. Participants will receive either the drug or a placebo twice over 12 months to see if it safely lowers triglyceride levels. The goal is to find a new treatment option for people already on statin therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Akademiska Sjukhuset Uppsala
RECRUITING

Uppsala, Sweden

Contact
AkardoMedSite
RECRUITING

Stockholm, Sweden

Contact
Lunds Universitetssjukhus
RECRUITING

Lund, Sweden

Contact
Ribocure Clinic/Ribocure Pharmaceuticals AB
RECRUITING

Mölndal, Sweden

Contact

Conditions

Explore the condition pages connected to this study.

DYSLIPIDEMIAS